Androgen deprivation therapy and cardiological risks in patients with prostate cancer. Are all drugs the same?

Cover Page

Cite item

Full Text

Abstract

Prostate cancer (PCa) is the most common oncological disease in men in Russia. For a long time, long-term androgen deprivation therapy (ADT) decreasing native testosterone level has been the basis of PCa drug therapy. At the time of PCa diagnosis, 2/3 of men have various risk factors for cardiovascular diseases (CVDs) or established CVDs (one fourth of the patients have CVDs associated with atherosclerosis; 45 % have a diagnosis of arterial hypertension). ADT is associated with increased risk of CVD and cardiovascular complications (CVC) development. Patients with PCa die of 2 main causes: directly due to cancer or due to CVD. Previously, luteinizing hormone-releasing hormone (LHRH) antagonists were considered to have a better safety profile compared to LHRH agonists. Comparison of all LHRH agonists (leuprorelin, triptorelin, goserelin, buserelin) with LHRH antagonists in meta-analyses showed that the risk of serious CVCs during LHRH antagonist therapy was 43 % lower than during agonist therapy. However, comparison of leuprorelin with antagonists did not show a significant difference in CVC rate. Leuprorelin is a drug with the most favorable profile of cardiological safety among the ADT drugs and the most frequently used LHRH agonist in the world. Considering high risk of CVDs and CVCs in patients with PCa, along with treatment of the main disease, careful control and reduction of risks of CVD development from the moment of PCa diagnosis should be implemented, the patients must be informed on the necessity of healthy lifestyle, established CVDs should be treated with rational regimens of antihypertensive, hypolipidemic, and hypoglycemic drugs. Risk control and reduction, as well as CVD treatment, should be performed for the whole duration of ADT. The article proposes an algorithm of cardiometabolic risk stratification prior to ADT initiation and during ADT.

About the authors

B. Ya. Alekseev

National Medical Research Radiological Center, Ministry of Health of Russia;
Medical Institute of Continuing Education, Russian Biotechnological University

ORCID iD: 0000-0002-3398-4128

3 2nd Botkinskiy Proezd, Moscow 125284,

11 Volokolamskoe Shosse, Moscow 125080

Russian Federation

V. M. Perepukhov

National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-7280-2553

3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

K. M. Nyushko

National Medical Research Radiological Center, Ministry of Health of Russia;
Medical Institute of Continuing Education, Russian Biotechnological University

Author for correspondence.
Email: kirandja@yandex.ru
ORCID iD: 0000-0002-4171-6211

Kirill M. Nyushko

3 2nd Botkinskiy Proezd, Moscow 125284,

11 Volokolamskoe Shosse, Moscow 125080

Russian Federation

M. G. Poltavskaya

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-4463-2897

Build. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

References

  1. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. doi: 10.3322/caac.21660
  2. State of oncological care in Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 262 p. (In Russ.).
  3. Prostate cancer. Clinical guidelines. Ministry of Health of Russia, 2021. (In Russ.).
  4. Jonušas J., Drevinskaitė М., Patašius А. et al. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study. Aging Male 2022;25(1):173–9. doi: 10.1080/13685538.2022.2091130
  5. Keating N.L., O’Malley A.J., Freedland S.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102(1):39–46. doi: 10.1093/jnci/djp404
  6. Saigal C.S., Gore J.L., Krupski T.L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493–500. doi: 10.1002/cncr.22933
  7. Van Hemelrijck M., Garmo H., Holmberg L. et al. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol 2012;61(4):690–700. doi: 10.1016/j.eururo.2011.09.010
  8. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1736–88. doi: 10.1016/S0140-6736(18)32203-7
  9. Mensah G.A., Fuster V., Murray C.J.L. et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol 2023;82(25):2350–473. doi: 10.1016/j.jacc.2023.11.007
  10. Armenian S.H., Xu L., Ky B. et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 2016;34(10):1122–30. doi: 10.1200/JCO.2015.64.0409
  11. Mulrooney D.A., Yeazel M.W., Kawashima T. et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606. doi: 10.1136/bmj.b4606
  12. Haugnes H.S., Wethal T., Aass N. et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28(30):4649–57. doi: 10.1200/JCO.2010.29.9362
  13. Lenihan D.J., Cardinale D.M. Late cardiac effects of cancer treatment. J Clin Oncol 2012;30(30):3657–64. doi: 10.1200/JCO.2012.45.2938
  14. Coleman M.P., Gatta G., Verdecchia A. et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14:v128–49. doi: 10.1093/annonc/mdg756
  15. Sturgeon K.M., Deng L., Bluethmann S.M. et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40(48):3889–97. doi: 10.1093/eurheartj/ehz766
  16. Leong D.P., Fradet V., Shayegan B. et al. Cardio- vascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol 2020;203(6):1109–16. doi: 10.1097/JU.0000000000000714
  17. Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropinreleasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5):1835–42. doi: 10.1016/j.juro.2011.07.035
  18. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. Cancer J Clin 2022;72(1):7–33. doi: 10.3322/caac.21708
  19. Klimis H., Pinthus J.H., Aghel N. et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis. JACC CardioOncol 2023;5(1):70–81. doi: 10.1016/j.jaccao.2022.09.008
  20. Goodale T., Sadhu A., Petak S., Robbins R. Testosterone and the heart. Methodist Debakey Cardiovasc J 2017;13(2):68–72. doi: 10.14797/mdcj-13-2-68
  21. Brouillette J., Rivard K., Lizotte E., Fiset C. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res 2005;65(1):148–57. doi: 10.1016/j.cardiores.2004.09.012
  22. Tsang S., Wu S., Liu J., Wong T.M. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α1-adrenoceptor stimulation. Br J Pharmacol 2008;153(4): 693–709. doi: 10.1038/sj.bjp.0707624
  23. Campelo A.E., Cutini P.H., Massheimer V.L. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol 2012;213(1):77–87. doi: 10.1530/JOE-11-0441
  24. Scragg J.L., Jones R.D., Channer K.S. et al. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochem Biophys Res Commun 2004;318(2):503–6. doi: 10.1016/j.bbrc.2004.04.054
  25. Tzortzis V., Samarinas M., Zachos I. et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones 2017;16(2):115–23. doi: 10.14310/horm.2002.1727
  26. Panagiotis M.I., Papatsoris A.G., Siasos G. et al. The effect of androgen deprivation therapy in arterial stiffness of the aorta and the endothelial function of peripheral arteries. Urol Nephrol Open Access J 2014;1(2):42–5.
  27. Hopmans S.N., Duivenvoorden W.C., Werstuck G.H. et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 2014;32(8):1126–34. doi: 10.1016/j.urolonc.2014.06.018
  28. Poljak Z., Hulin I., Maruscakova L., Mladosievicova B. Are GnRH and FSH potentially damaging factors in the cardiovascular system? Pharmazie 2018;73(4):187–90. doi: 10.1691/ph.2018.7992
  29. Crawford E.D., Schally A.V., Pinthus J.H. et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol 2017;35(5):183–91. doi: 10.1016/j.urolonc.2017.01.025
  30. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008;29(5):534–9. doi: 10.2164/jandrol.108.005454
  31. Wang T., Li M., Zeng T. et al. Association between insulin resistance and cardiovascular disease risk varies according to glucose tolerance status: a nationwide prospective cohort study. Diabetes Care 2022;45(8):1863–72. doi: 10.2337/dc22-0202
  32. Herink M., Ito M.K. Medication induced changes in lipid and lipoproteins. Eds.: K.R. Feingold, B. Anawalt, M.R. Blackman et al. Endotext. MDText.com, Inc, 2000.
  33. Pol T., Held C., Westerbergh J. et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. J Am Heart Assoc 2018;7(3):e007444. doi: 10.1161/JAHA.117.007444
  34. Katsoulis M., Stavola B.D., Diaz-Ordaz K. et al. Weight change and the onset of cardiovascular diseases: emulating trials using electronic health records. Epidemiology 2021;32(5):744–55. doi: 10.1097/EDE.0000000000001393
  35. Seible D.M., Gu X., Hyatt A., Beard C. Identifying men at greatest risk of weight gain from androgen deprivation therapy. J Clin Oncol 2014;32(4_suppl):80. doi: 10.1200/jco.2014.32.4_suppl.80
  36. Nelson A.J., Lopes R.D., Hong H. et al. Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: a systematic review. JACC CardioOncol 2023;5(5):613–24. doi: 10.1016/j.jaccao.2023.05.011
  37. Cicione A., Nacchia A., Guercio A. et al. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. Prostate Cancer Prostatic Dis 2023;26(4):765–71. doi: 10.1038/s41391-022-00640-4
  38. Lopes R.D., Higano C.S., Slovin S.F. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;144(16):1295–307. doi: 10.1161/CIRCULATIONAHA.121.056810
  39. Kokorovic A., So A.I., Serag H. et al. UPDATE–Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J 2022;16(8): E416–31. doi: 10.5489/cuaj.8054
  40. Crawford E.D., Hafron J.M., Debruyne F. et al. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. J Urol 2024;211(1):63–70. doi: 10.1097/JU.0000000000003721
  41. Crawford E.D., Hafron J.M., Tagawa S.T. et al. Impact of late dosing on testosterone suppression with 2 different leuprolide acetate formulations: in situ gel and microsphere. An Analysis of United States Clinical Data. J Urol 2021;205(2):554–60. doi: 10.1097/JU.0000000000001392
  42. Patel S., Zhu K., Dav C.V. et al. Comparative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists among patients diagnosed with prostate cancer: a systematic review and meta-analysis of real-world evidence studies. Eur Urol Oncol 2024;S2588-9311(24)00213-X. doi: 10.1016/j.euo.2024.09.004
  43. Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997;28(1):43–70. doi: 10.1016/s0169-409x(97)00050-1
  44. Fujino M., Fukuda T., Shinagawa S. et al. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem Biophys Res Commun 1974;60(1): 406–13. doi: 10.1016/0006-291x(74)90219-8
  45. Abouelfadel Z., Crawford E.D. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag 2008;4(2):513–26. doi: 10.2147/tcrm.s686
  46. Özyi̇ği̇t G., Akyol F. Cost-effectiveness analysis of leuprorelin acetate atrigel in the treatment of prostate cancer. Turkish Journal of Oncology 2020;35(4):430–7. doi: 10.5505/tjo.2020.2449
  47. The European Medicines. Available at: Agencyhttps://www.ema.europa.eu/en/medicines/human/referrals/leuprorelin-containing-depotmedicinal-products
  48. Tombal B., Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005; 4(8):30–6. doi: 10.1016/J.EURSUP.2005.08.004
  49. Dadey E.J. The atrigel drug delivery system. Modified-release drug delivery technology. CRC Press, 2008. Pp. 211–218.
  50. Kempe S., Mäder K. In situ forming implants – an attractive formulation principle for parenteral depot formulations. J Control Release 2012;161(2):668–79. doi: 10.1016/j.jconrel.2012.04.016
  51. Shimoyama M., Murata Y., Sumi K. et al. Docetaxel induced cardiotoxicity. Heart 2001;86:219. doi: 10.1136/heart.86.2.219
  52. Bendahou H., Ettagmouti Y., Abouriche A. et al. Cardiotoxicity due to docetaxel rare but it exists: about a case and literature review. J Case Rep Med Hist 2023;3(1). doi: 10.54289/JCRMH2300105
  53. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506
  54. Beer T.M., Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. doi: 10.1056/NEJMc1410239
  55. Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. doi: 10.1056/NEJMoa1903835
  56. Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465–74. doi: 10.1056/NEJMoa1800536
  57. Salem J.E., Yang T., Moslehi J.J. et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019;140(13): 1070–80. doi: 10.1161/CIRCULATIONAHA.119.040162
  58. Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. doi: 10.1056/NEJMoa1715546
  59. Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13–24. doi: 10.1056/NEJMoa1903307
  60. Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–46. doi: 10.1056/NEJMoa1815671
  61. Smith M.R., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132–42. doi: 10.1056/NEJMoa2119115
  62. O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17α-hydroxylase/C17, 20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317–25. doi: 10.1038/sj.bjc.6601879
  63. Attard G., Reid A.H.M., Auchus R.J. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97(2):507–16. doi: 10.1210/jc.2011-2189
  64. De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618
  65. Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. doi: 10.1056/NEJMoa1209096
  66. Fizazi K., Tran N.P., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. doi: 10.1056/NEJMoa1704174
  67. Zhu X., Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens 2019;25:1–9. doi: 10.1186/s40885-019-0110-3
  68. Salem J.E., Alexandre J., Bachelot A., Funck-Brentano C. Influence of steroid hormones on ventricular repolarization. Pharmacol Ther 2016;167:38–47. doi: 10.1016/j.pharmthera.2016.07.005
  69. Iacovelli R., Ciccarese C., Bria E. et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16(3):e645–53. doi: 10.1016/j.clgc.2017.12.007
  70. Lu-Yao G., Nikita N., Keith S.W. et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020;77(2):158–66. doi: 10.1016/j.eururo.2019.07.031
  71. Verzoni E., Grassi P., Ratta R. et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther Adv Med Oncol 2016;8(5):323–30. doi: 10.1177/1758834016656493
  72. Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;23(10):e333–465. doi: 10.1093/eurheartj/ehac244
  73. Boytsov S.A., Pogosova N.V., Ansheles A.A. et al. Cardiovascular prevention 2022. Russian national guidelines. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology 2023;28(5):5452. (In Russ.). doi: 10.15829/1560-4071-2023-5452
  74. Vitsenya M.V., Ageev F.T., Orlova R.V. et al. Practical recommendations for correction of cardiovascular toxicity of antitumor drug therapy. RUSSCO Practical Recommendations, Part 2. Zlokachestvennye opukholi = Malignant Tumours 2023;13(#3s2):86–111. (In Russ.).
  75. Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021;42(34):3227–37.
  76. Okwuosa T.M., Morgans A., Rhee J.W. et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med 2021;14(3):e000082. doi: 10.1161/HCG.0000000000000082
  77. Wilk M., Waśko-Grabowska A., Skoneczna I., Szmit S. Angiotensin system inhibitors may improve outcomes of patients with castrationresistant prostate cancer during abiraterone acetate treatment— a cardio-oncology study. Front Oncol 2021;11:664741. doi: 10.3389/fonc.2021.664741
  78. Salem J.E., Waintraub X., Courtillot C. et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation 2018;138(1):110–3. doi: 10.1161/CIRCULATIONAHA.118.034282
  79. Crawford E.D., Garnick M.B., Eckel R.H. et al. A proposal for the comprehensive care of men on androgen deprivation therapy: recommendations from the multidisciplinary Prostate Cancer 360 Working Group. Urol Pract 2024;11(1):18–29. doi: 10.1097/UPJ.0000000000000473
  80. Goff Jr D.C., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 suppl 2):S49–73. doi: 10.1161/01.cir.0000437741.48606.98
  81. Jayalath V.H., Clark R., Lajkosz K. et al. Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis. JAMA Netw Open 2022;5(11):e2242676. doi: 10.1001/jamanetworkopen.2022.42676
  82. General characteristics of the Erleada pharmaceutical (01.09.2023). Available at: http://eec.eaeunion.org/ (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36986 от  21.07.2009.